Urinary and tissue monocyte chemoattractant protein1 (MCP1) in lupus nephritis patients

Urinary MCP-1 and TWEAK as non-invasive markers of disease activity and treatment response in patients with lupus nephritis in South Africa

“…One study from China reported a higher concentration of both biomarkers in the urine of patients with active LN compared to those with non-active disease (P<0.01) and also showed signi cant correlation between both biomarkers and kidney biopsy activity index (P<0.01) but not with chronicity index of the biopsies (P>0.05) [11] Similar ndings have been reported by other studies. [12] Although our study did not demonstrate correlation between the biomarkers and renal activity scores, we think this may be related to the low sample size of our study given that other clinical and biochemical markers of activity were elevated at baseline and declined following treatment. This could suggest that these biomarkers can be useful for monitoring renal disease ares which are more aggressive and often more frequent in non-Caucasian populations.…”

“…[5] When measured in the urine, novel biomarkers such as monocyte chemoattractant protein-1 (MCP-1) and tumour necrosis factor-related weak inducer of apoptosis (TWEAK) may be useful for monitoring disease activity, and assessing response to therapy as they are secreted within the kidney during in ammation. [11][12][13] MCP-1 is a chemokine responsible for monocyte and T-lymphocyte recruitment during the acute and chronic phases of in ammation, [14] while TWEAK is a pro-in ammatory cytokine produced mainly by innate immune cells resulting in glomerular and tubular injury. [15] Hence, both biomarkers can be easily measured in urine and could be useful for disease monitoring in patients with LN receiving treatment.…”

Urinary MCP-1 and TWEAK as non-invasive markers of disease activity and treatment response in patients with lupus nephritis in South Africa

“…[11,25,27,28] Most of these studies have to those with non-active disease (P < 0.01) and also showed significant correlation between both biomarkers and kidney biopsy activity index (P < 0.01) but not with chronicity index of the biopsies (P > 0.05) [11] Similar findings have been reported by other studies. [12] Although our study did not demonstrate correlation between the biomarkers and renal activity scores, we think this may be related to the low sample size of our study given that other clinical and biochemical markers of activity were elevated at baseline and declined following treatment. This could suggest that these biomarkers can be useful for monitoring renal disease flares which are more aggressive and often more frequent in non-Caucasian populations.…”

“…[5] When measured in the urine, novel biomarkers such as monocyte chemoattractant protein-1 (MCP- 1) and tumour necrosis factor-related weak inducer of apoptosis (TWEAK) may be useful for monitoring disease activity, and assessing response to therapy as they are secreted within the kidney during inflammation. [11][12][13] MCP-1 is a chemokine responsible for monocyte and T-lymphocyte recruitment during the acute and chronic phases of inflammation, [14] while TWEAK is a pro-inflammatory cytokine produced mainly by innate immune cells resulting in glomerular and tubular injury. [15] Our study aim was to assess the value of uMCP-1 and uTWEAK as markers of disease activity and treatment response in South Africans with biopsy proven LN.…”

Diagnostic value of urinary monocyte chemoattractant protein-1 in evaluating the activity of lupus nephritis: a meta-analysis

“…To date, many studies have found that the indicator of urinary MCP-1(uMCP-1) is related to the activity of LN renal lesions and could be used as a diagnostic biomarker for active LN. 10–16 Due to the small sample size of individual studies and the varying levels of sensitivity and specificity in each study, we further evaluated the diagnostic value of uMCP-1 for active LN through this meta-analysis.…”